Cross-neutralization of Omicron subvariants after heterologous NVX-CoV2373 boosters: Comparison between prior SARS-CoV-2-infected and infection-naive individuals

Reduced neutralizing antibody response in naïve Covishield vaccinees against Omicron emphasizes booster vaccination

(2022) Pragya D. Yadav et al.   JOURNAL OF INFECTION

Robust neutralizing antibody responses after single-dose BNT162b2 vaccination at long intervals from prior SARS-CoV-2 infection and ceiling effect with repeated vaccination

(2022) Ji Yun Noh et al.   JOURNAL OF INFECTION

Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial

(2022) Raburn M Mallory et al.   LANCET INFECTIOUS DISEASES

Prior Omicron infection protects against BA.4 and BA.5 variants

(2022) McKenzie Prillaman   NATURE

Longitudinal assessment of anti-SARS-CoV-2 immune responses for six months based on the clinical severity of COVID-19

(2021) Ji Yun Noh et al.   JOURNAL OF INFECTIOUS DISEASES

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET